Primary Site >> Stomach Cancer
Gene >> CD274
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: In situ expression and significance of B7 costimulatory molecules within tissues of human gastric carcinoma. PMID: 12800259 |
Ref: Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. PMID: 16530813 |
Ref: PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies. PMID: 17212704 |
Ref: [Expression and significance of B7-H1 and its receptor PD-1 in human gastric carcinoma]. PMID: 18756934 |
Ref: T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract. PMID: 21717068 Ref: Increased B7-H1 and B7-H4 Expressions on Circulating Monocytes and Tumor-Associated Macrophages are Involved in Immune Evasion in Patients with Gastric Cancer. PMID: 24031123 |
Ref: A frequent somatic mutation in CD274 3'-UTR leads to protein over-expression in gastric cancer by disrupting miR-570 binding. PMID: 22190470 Ref: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. PMID: 22658128 |
Ref: Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications. PMID: 24653632 Ref: Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer. PMID: 24657498 Ref: Comprehensive molecular characterization of gastric adenocarcinoma. PMID: 25079317 Ref: The role of B7-H1 in gastric carcinoma: clinical significance and related mechanism. PMID: 25311064 Ref: B7-H1 expression associates with tumor invasion and predicts patient's survival in human esophageal cancer. PMID: 25337246 |
Ref: Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance. PMID: 24804867 Ref: Genomic assays for Epstein-Barr virus-positive gastric adenocarcinoma. PMID: 25613731 Ref: Update on Epstein-Barr virus and gastric cancer (review). PMID: 25633561 Ref: Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer. PMID: 25733810 Ref: B7-H1 enhances proliferation ability of gastric cancer stem-like cells as a receptor. PMID: 25789052 Ref: Molecular classification of gastric adenocarcinoma: translating new insights from the cancer genome atlas research network. PMID: 25813036 Ref: Wogonin Inhibits Tumor-derived Regulatory Molecules by Suppressing STAT3 Signaling to Promote Tumor Immunity. PMID: 25962106 Ref: PD-L1 and Survival in Solid Tumors: A Meta-Analysis. PMID: 26114883 Ref: Comparison of variations detection between whole-genome amplification methods used in single-cell resequencing. PMID: 26251698 Ref: Epstein-Barr Virus-Associated Gastric Carcinoma: Use of Host Cell Machineries and Somatic Gene Mutations. PMID: 26337667 Ref: Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations. PMID: 26487950 Ref: Clinicopathologic Significance and Prognostic Value of B7 Homolog 1 in Gastric Cancer: A Systematic Review and Meta-Analysis. PMID: 26512615 Ref: Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors. PMID: 26617827 |
Ref: The prediction of survival of patients with gastric cancer with PD-L1 expression using contrast-enhanced ultrasonography. PMID: 26671554 Ref: [Progression of immunotherapy in gastric cancer]. PMID: 26831889 Ref: Advances of Molecular Targeted Therapy in Gastric Cancer. PMID: 26875080 Ref: Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints. PMID: 26880697 Ref: Expression and prognostic roles of PIK3CA, JAK2, PD-L1, and PD-L2 in Epstein-Barr virus-associated gastric carcinoma. PMID: 26980034 Ref: Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives. PMID: 27039171 Ref: Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. PMID: 27138582 Ref: Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers. PMID: 27147580 Ref: Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. PMID: 27157491 Ref: Programmed death-ligand-1 expression in advanced gastric cancer detected with RNA in situ hybridization and its clinical significance. PMID: 27191996 Ref: Recent updates of precision therapy for gastric cancer: Towards optimal tailored management. PMID: 27217696 Ref: Biomarkers of EBV-positive Gastric Cancers: Loss of PTEN Expression is Associated with Poor Prognosis and Nodal Metastasis. PMID: 27221363 Ref: Prognostic significance of PD-L1 expression in patients with gastric cancer in East Asia: a meta-analysis. PMID: 27226727 Ref: Therapeutic Antibodies in Cancer Therapy. PMID: 27236554 Ref: Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer. PMID: 27256004 Ref: [New molecular classification of colorectal cancer, pancreatic cancer and stomach cancer: Towards "a la carte" treatment?]. PMID: 27345450 Ref: Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability. PMID: 27465786 Ref: Gastric biomarkers: a global review. PMID: 27514667 Ref: PD-L1 expression in human cancers and its association with clinical outcomes. PMID: 27574444 Ref: Immunotherapy for Gastroesophageal Cancer. PMID: 27669318 Ref: Concordance of immune checkpoints within tumor immune contexture and their prognostic significance in gastric cancer. PMID: 27720576 Ref: The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1. PMID: 27747091 Ref: Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention. PMID: 27766079 Ref: Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer. PMID: 27803740 Ref: The Future Prospects of Immune Therapy in Gastric and Esophageal Adenocarcinoma. PMID: 27854242 Ref: The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients. PMID: 27892511 |
Ref: Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer. PMID: 27241062 Ref: Epstein-Barr Virus-associated Gastric Cancer and Potential Mechanisms of Oncogenesis. PMID: 27677953 Ref: A polymorphism in the promoter region of PD-L1 serves as a binding-site for SP1 and is associated with PD-L1 overexpression and increased occurrence of gastric cancer. PMID: 27889799 Ref: Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1(+) immune cells in Epstein-Barr virus-associated gastric cancer: the prognostic implications. PMID: 27934877 Ref: Proteogenomic analysis of NCC-S1M, a gastric cancer stem cell-like cell line that responds to anti-PD-1. PMID: 28153736 Ref: The prognostic value and pathobiological significance of Glasgow microenvironment score in gastric cancer. PMID: 28180998 Ref: New agents on the horizon in gastric cancer. PMID: 28184417 Ref: PD-L1/PD-1 check-point in gastric carcinoma with lymphoid stroma case report with immunochemical study. PMID: 28207501 Ref: Knockdown of PD-L1 in Human Gastric Cancer Cells Inhibits Tumor Progression and Improves the Cytotoxic Sensitivity to CIK Therapy. PMID: 28222426 Ref: Predictive biomarkers along gastric cancer pathogenetic pathways. PMID: 28277834 Ref: Neutrophils diminish T-cell immunity to foster gastric cancer progression: the role of GM-CSF/PD-L1/PD-1 signalling pathway. PMID: 28348197 Ref: Immunotherapy for gastric cancers: emerging role and future perspectives. PMID: 28349740 Ref: Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody. PMID: 28405494 Ref: Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients. PMID: 28412752 Ref: The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy. PMID: 28418918 Ref: MicroRNA-152 regulates immune response via targeting B7-H1 in gastric carcinoma. PMID: 28427226 Ref: Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis. PMID: 28471952 Ref: Immunochemotherapy benefits in gastric cancer patients stratified by programmed death-1 ligand-1. PMID: 28501128 Ref: The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy? PMID: 28507801 Ref: A gene polymorphism in PD-L1 promoter region is not associated with PD-L1 expression and patients' survival in gastric cancer. PMID: 28540431 Ref: Immunotherapy for Esophageal and Gastric Cancer. PMID: 28561677 Ref: A Four-Factor Immunoscore System That Predicts Clinical Outcome for Stage II/III Gastric Cancer. PMID: 28619967 Ref: Clonality analysis of synchronous gastro-oesophageal junction carcinoma and distal gastric cancer by whole-exome sequencing. PMID: 28671728 Ref: Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma. PMID: 28754154 Ref: PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence. PMID: 28757801 Ref: Prognostic and predictive values of PD-L1 expression in patients with digestive system cancer: a meta-analysis. PMID: 28769571 Ref: Association between PD-L1 Expression on Tumour-Infiltrating Lymphocytes and Overall Survival in Patients with Gastric Cancer. PMID: 28775777 Ref: Immunotherapeutic Strategies for Gastric Carcinoma: A Review of Preclinical and Clinical Recent Development. PMID: 28781967 Ref: Folic acid-functionalized polyethylenimine superparamagnetic iron oxide nanoparticles as theranostic agents for magnetic resonance imaging and PD-L1 siRNA delivery for gastric cancer. PMID: 28794626 Ref: PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis. PMID: 28796808 Ref: Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma. PMID: 28910818 Ref: Combined prognostic effect of PD-L1 expression and immunoscore in microsatellite-unstable advanced gastric cancers. PMID: 28938605 Ref: Differentiated tumor immune microenvironment of Epstein-Barr virus-associated and negative gastric cancer: implication in prognosis and immunotherapy. PMID: 28978018 Ref: Understanding immune phenotypes in human gastric disease tissues by multiplexed immunohistochemistry. PMID: 29025424 Ref: Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer. PMID: 29073638 Ref: Diagnostic, Predictive, Prognostic, and Therapeutic Molecular Biomarkers in Third Millennium: A Breakthrough in Gastric Cancer. PMID: 29094049 Ref: Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types. PMID: 29212506 Ref: [Checkpoint Inhibitors in the Treatment of Upper Gastrointestinal Tract Tumors]. PMID: 29239193 Ref: Predictive relevance of PD-L1 expression with pre-existing TILs in gastric cancer. PMID: 29245908 Ref: IFNgamma induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma. PMID: 29259270 Ref: Current Targeted Therapies in HER2-Positive Gastric Adenocarcinoma. PMID: 29265917 Ref: [Current Status of Checkpoint Inhibitors in the Treatment of Esophageal and Gastric Tumors - Overview of Studies]. PMID: 29488776 Ref: LBA-009KEYNOTE-059 cohort 3: safety and efficacy of pembrolizumab monotherapy for first-line treatment of patients (pts) with PD-L1-positive advanced gastric/gastroesophageal (G/GEJ) cancer. PMID: 30052791 |
Ref: PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. PMID: 29034543 Ref: Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer. PMID: 29155997 Ref: Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression. PMID: 29277762 Ref: Programmed death-ligand 1 is a promising blood marker for predicting tumor progression and prognosis in patients with gastric cancer. PMID: 29345842 Ref: Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information. PMID: 29360924 Ref: Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients. PMID: 29399387 Ref: Gastric Carcinomas With Lymphoid Stroma: An Evaluation of the Histopathologic and Molecular Features. PMID: 29438172 Ref: Molecular Characterization of Gastric Carcinoma: Therapeutic Implications for Biomarkers and Targets. PMID: 29522457 Ref: Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer. PMID: 29534305 Ref: Upper gastrointestinal malignancies in 2017: current perspectives and future approaches. PMID: 29542354 Ref: Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. PMID: 29543932 Ref: Immunoclassification characterized by CD8 and PD-L1 expression is associated with the clinical outcome of gastric cancer patients. PMID: 29552300 Ref: EBV(+) and MSI Gastric Cancers Harbor High PD-L1/PD-1 Expression and High CD8(+) Intratumoral Lymphocytes. PMID: 29614789 Ref: Nivolumab-induced acute granulomatous tubulointerstitial nephritis in a patient with gastric cancer. PMID: 29623482 Ref: Poor prognosis in Epstein-Barr virus-negative gastric cancer with lymphoid stroma is associated with immune phenotype. PMID: 29627937 Ref: [Predictive diagnostics of gastric cancer in 2018]. PMID: 29631408 Ref: Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability. PMID: 29636988 Ref: Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status. PMID: 29673110 Ref: First Report of Dramatic Tumor Responses with Ramucirumab and Paclitaxel After Progression on Pembrolizumab in Two Cases of Metastatic Gastroesophageal Adenocarcinoma. PMID: 29674442 Ref: CXCL9/10/11, a regulator of PD-L1 expression in gastric cancer. PMID: 29690901 Ref: Immune Checkpoint Inhibition in Gastro-Oesophageal Cancer. PMID: 29705787 Ref: Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica. PMID: 29714649 Ref: Genetic features of multicentric/multifocal intramucosal gastric carcinoma. PMID: 29717480 Ref: Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study. PMID: 29727332 Ref: Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives. PMID: 29730461 Ref: Clinical Importance of Epstein(-)Barr Virus-Associated Gastric Cancer. PMID: 29843478 Ref: PD-L1 Expression Predicts a Distinct Prognosis in Krukenberg Tumor with Corresponding Origins. PMID: 29854854 Ref: Current and future biomarkers in gastric cancer. PMID: 29864959 Ref: PD-L1 expression is a prognostic factor in subgroups of gastric cancer patients stratified according to their levels of CD8 and FOXP3 immune markers. PMID: 29872566 Ref: Gastritis-Infection-Cancer Sequence of Epstein-Barr Virus-Associated Gastric Cancer. PMID: 29896679 Ref: Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes. PMID: 29915957 Ref: Tristetraprolin Overexpression in Gastric Cancer Cells Suppresses PD-L1 Expression and Inhibits Tumor Progression by Enhancing Antitumor Immunity. PMID: 29936792 Ref: Mouse-Derived Gastric Organoid and Immune Cell Co-culture for the Study of the Tumor Microenvironment. PMID: 29959712 Ref: PD-L1 Expression and CD8(+) T Cell Infiltration Predict a Favorable Prognosis in Advanced Gastric Cancer. PMID: 30003113 Ref: Is high serum programmed death ligand 1 level a risk factor for poor survival in patients with gastric cancer? PMID: 30003194 Ref: Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. PMID: 30013197 Ref: The Transcriptomic Landscape of Gastric Cancer: Insights into Epstein-Barr Virus Infected and Microsatellite Unstable Tumors. PMID: 30018250 Ref: Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer. PMID: 30028179 Ref: Avelumab inducing hypothyroidism and hypoadrenalism: A case report and review of literature. PMID: 30034316 Ref: [Relationship between PD-L1 protein expression and gene amplification in gastric cancer tissues]. PMID: 30107664 Ref: FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1. PMID: 30120163 Ref: LPS promotes the expression of PD-L1 in gastric cancer cells through NF-kappaB activation. PMID: 30145830 Ref: The roles of PD-1/PD-L1 and its signalling pathway in gastrointestinal tract cancers. PMID: 30161295 Ref: Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches. PMID: 30173350 Ref: Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists. PMID: 30196908 Ref: Prognostic Impact of Immune-Related Gene Expression in Preoperative Peripheral Blood from Gastric Cancer Patients. PMID: 30203407 Ref: Gastric cancer mesenchymal stem cells derived IL-8 induces PD-L1 expression in gastric cancer cells via STAT3/mTOR-c-Myc signal axis. PMID: 30206229 Ref: The clinical significance of PD-L1 in advanced gastric cancer is dependent on ARID1A mutations and ATM expression. PMID: 30221053 Ref: Computational measurement of tumor immune microenvironment in gastric adenocarcinomas. PMID: 30224753 Ref: What Will We Expect From Novel Therapies to Esophageal and Gastric Malignancies? PMID: 30231398 Ref: Somatic mutational profiles of stage II and III gastric cancer according to tumor microenvironment immune type. PMID: 30239046 Ref: EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions. PMID: 30264329 Ref: Immune Therapeutics in the Treatment of Advanced Gastric and Esophageal Cancer. PMID: 30275174 Ref: Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial. PMID: 30282452 Ref: Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8(+) T cells in the tumor microenvironment. PMID: 30314524 Ref: Pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer: an evidence-based review of place in therapy. PMID: 30323626 Ref: MiR-940 Promotes the Proliferation and Migration of Gastric Cancer Cells through Up-regulation of Programmed Death Ligand-1 Expression. PMID: 30367831 Ref: Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design. PMID: 30379568 |